BLI Banque de Luxembourg Investments Reduces Holdings in Gilead Sciences, Inc. $GILD

BLI Banque de Luxembourg Investments lowered its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 7.8% in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 20,031 shares of the biopharmaceutical company’s stock after selling 1,700 shares during the quarter. BLI Banque de Luxembourg Investments’ holdings in Gilead Sciences were worth $2,216,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Activest Wealth Management increased its stake in shares of Gilead Sciences by 2,837.5% in the first quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 227 shares in the last quarter. GoalVest Advisory LLC boosted its holdings in Gilead Sciences by 7,566.7% in the 2nd quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 227 shares during the period. Harbor Asset Planning Inc. bought a new position in Gilead Sciences in the 2nd quarter worth approximately $27,000. Putney Financial Group LLC grew its stake in Gilead Sciences by 53.4% in the 2nd quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 94 shares in the last quarter. Finally, Colonial Trust Advisors raised its holdings in Gilead Sciences by 304.3% during the 1st quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 213 shares during the period. 83.67% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the company. Morgan Stanley raised their price target on Gilead Sciences from $143.00 to $147.00 and gave the stock an “overweight” rating in a report on Friday, October 31st. Scotiabank started coverage on Gilead Sciences in a research note on Thursday, November 13th. They issued a “sector outperform” rating and a $140.00 target price for the company. Dbs Bank upgraded Gilead Sciences to a “moderate buy” rating in a research report on Friday, September 5th. Royal Bank Of Canada increased their price target on shares of Gilead Sciences from $100.00 to $105.00 and gave the stock a “sector perform” rating in a report on Friday, October 31st. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Gilead Sciences from $145.00 to $150.00 and gave the company an “overweight” rating in a research note on Friday, October 31st. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat, Gilead Sciences presently has an average rating of “Moderate Buy” and an average target price of $130.65.

Gilead Sciences Trading Down 1.3%

Shares of GILD stock opened at $125.85 on Monday. The business has a 50-day moving average price of $119.87 and a two-hundred day moving average price of $114.70. Gilead Sciences, Inc. has a 12-month low of $88.57 and a 12-month high of $128.70. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13. The firm has a market cap of $156.13 billion, a P/E ratio of 25.07, a price-to-earnings-growth ratio of 0.81 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share for the quarter, beating analysts’ consensus estimates of $2.16 by $0.31. The company had revenue of $7.77 billion for the quarter, compared to analysts’ expectations of $7.42 billion. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.Gilead Sciences’s revenue for the quarter was up 3.0% compared to the same quarter last year. During the same period last year, the firm posted $2.02 EPS. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. Equities analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 30th. Shareholders of record on Monday, December 15th will be paid a dividend of $0.79 per share. The ex-dividend date of this dividend is Monday, December 15th. This represents a $3.16 annualized dividend and a dividend yield of 2.5%. Gilead Sciences’s dividend payout ratio (DPR) is 48.99%.

Insider Buying and Selling at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction on Monday, November 17th. The shares were sold at an average price of $125.23, for a total value of $313,075.00. Following the transaction, the chief financial officer owned 154,555 shares in the company, valued at $19,354,922.65. This trade represents a 1.59% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Daniel Patrick O’day sold 10,000 shares of the business’s stock in a transaction on Tuesday, October 28th. The stock was sold at an average price of $119.39, for a total transaction of $1,193,900.00. Following the completion of the sale, the chief executive officer directly owned 581,203 shares of the company’s stock, valued at $69,389,826.17. This represents a 1.69% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 115,146 shares of company stock valued at $14,012,141. Insiders own 0.27% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.